COMMUNIQUÉS West-GlobeNewswire

-
SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors
20/06/2025 -
Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference
20/06/2025 -
PETVIVO HOLDINGS, INC. ANNOUNCES INVESTOR EXERCISE OF PURCHASE OPTION TIED TO SERIES B CONVERTIBLE PREFERRED STOCK OFFERING
20/06/2025 -
Telix Precision Medicine Announces AlFluor Radiochemistry Platform
20/06/2025 -
Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML
20/06/2025 -
Firefly Neuroscience Researchers Uncover Powerful New Way of Objectively Measuring SCD, MCI, and Dementia in Alzheimer’s Patients
20/06/2025 -
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for QINLOCK® (ripretinib)
20/06/2025 -
GoPath Diagnostics Announces Launch of DiabetesNow: A Genetic Test Panel Designed to Clarify Diabetes Diagnosis
20/06/2025 -
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month
20/06/2025 -
IMBRUVICA® (ibrutinib) receives positive CHMP opinion for the treatment of patients with previously untreated mantle cell lymphoma (MCL) who would be eligible for autologous stem cell transplant
20/06/2025 -
DARZALEX® (daratumumab) receives the first positive CHMP opinion for patients with high-risk smouldering multiple myeloma
20/06/2025 -
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
20/06/2025 -
CHMP recommends third indication for darolutamide for patients with advanced prostate cancer
20/06/2025 -
Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
20/06/2025 -
Ipsen reçoit un avis positif du CHMP pour Cabometyx® dans les tumeurs neuroendocrines avancées précédemment traitées
20/06/2025 -
Dr. Anosh Ahmed’s Philanthropic Vision: Empowering Underserved Chicago Communities
20/06/2025 -
NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update
20/06/2025 -
Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
20/06/2025 -
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
20/06/2025
Pages